drugset / Trial / NCT00547664
Efficacy of Hylenex in the Treatment of Pain Among Hospice Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
The overall aim of this study is to find out whether Hylenex recombinant (for short, Hylenex) in subcutaneous (SC) injection improves the speed and effectiveness of SC opioids in hospice patients. Specifically, this study proposes to compare the level of self-reported pain in hospice patients started on SC infusions of morphine and hydromorphone (Dilaudid) over the initial 8 hours of opioid infusion with and without the preceded co-injection of Hylenex. Hospice patients include both home-bound patients as well as those under intensive care in hospice houses.
Timeline
- Start
- 2008-01
- Primary completion
- 2009-12
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rHuPH20 | Protein / enzyme biologic | — | Subcutaneous |
| Background | Hydromorphone | Other / unclassified | — | Subcutaneous |
| Background | Morphine | Other / unclassified | — | Subcutaneous |
Indications
No indication recorded.